Navigation Links
Steroid Treatment after head injury may be fatal

According to a report from Lancet, Patients with head injury who were treated with methylprednisolone had a significantly increased risk of death within //the following 2 weeks compared with untreated group of patients.

"Our early results show that corticosteroids should not be used routinely to treat head injury, whatever the severity," Dr. Ian Roberts. He is clinical coordinator of the CRASH (corticosteroid randomization after significant head injury) trial. In 1997, a systematic review suggested the risk of death could be reduced by up to 2% by treating head injury victims with steroids, the CRASH trial collaborators note. However, the 95% confidence interval ranged between 6% fewer to 2% more deaths.

CRASH was supposed to enrol 20,000 patients with Glasgow coma score of 14 or lower within 8 hours of head injury. However after studying 10,008 patients in 239 hospitals from 49 countries the trail found 21% mortality rate within 2 weeks for those treated with the 48-hour methylprednisolone infusion, versus 18% among those allocated placebo (relative risk 1.18, p = 0.0001).

"The relative increase in deaths due to corticosteroids did not differ by injury severity (p = 0.22) or time since injury (p = 0.05)," the authors note.

"By clearly refuting a mortality benefit from corticosteroids in head injury, the CRASH trial results should protect many thousands of patients from any increased risk of death associated with these drugs," they add. These findings could have similar implications for use of corticosteroids in spinal cord injury.

The lesson learnt from CRASH according to Dr. Stefan Sauerland, at the University of Cologne, and Dr. Marc Maegele at the University of Witten-Herdecke, in Germany, is that "we should avoid trusting in underpowered clinical trials with surrogate rather than clinical endpoints, and transferring evidence from one disease to another."


'"/>




Page: 1

Related medicine news :

1. Inhaled Steroids Safe & Effective for Children with Asthma
2. Mislabeled Body-building Steroid Supplements
3. Steroid Treatment for Wheezing Questioned
4. Steroid-Free Liver Transplants
5. The Use Of Steroids for Dizziness Questioned
6. Biofeedback Found To Reduce Steroid Dependence In Asthmatics
7. The Link Between High-dose Steroid Use And Heart Disease Questioned
8. The Use Of Oral Steroids For Muscular Dystrophy Questioned
9. No Steroids for Traumatic Brain Injury
10. Steroids Effective For Treating Carpel Tunnel Syndrome
11. FDA to bring about changes in Marketed Non-Steroidal Anti-Inflammatory Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/23/2017)... ... April 23, 2017 , ... Altura Communication Solutions, ... of Cisco Select certification and SMB specialization. Altura is now qualified to ... In earning the Select Certification, Altura fulfilled the training and exam requirements for ...
(Date:4/22/2017)... White Plains, NY (PRWEB) , ... April 22, ... ... Quarterly Report, which shows that U.S. consumers can save an average of 70% ... Even greater savings (up to 97%) are available when purchasing from other countries. ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article ... ancient teeth, which reveal a great deal about prehistoric ice-age dental practitioners and their ... have been used to remove decayed dental matter, and that teeth were then filled ...
(Date:4/21/2017)... ... 21, 2017 , ... Contrary to popular perception, a new ... at noteworthy rates. Between 2002 and 2014, Salas-Wright and his colleagues found a ... the United States. The study, Trends in Fighting and Violence Among Adolescents ...
(Date:4/21/2017)... ... ... Brady (NYSE:BRC), a global leader in industrial and safety printing ... vinyl label materials received certification for the BS5609 British Marine Standard. This internationally recognized ... for use on chemical drums shipped by sea. , ÔÇťAchieving BS5609 certification ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/19/2017)... Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will ... at the Sheraton Hotel in Toronto, Ontario . ... Company is scheduled to present on Tuesday, May 2 at 10:00 ... of the Board, Tony Holler will also attend the ... For more details about ...
Breaking Medicine Technology: